IXHL INCANNEX HEALTHCARE LTD

Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation containing data and analysis of the results from the Phase 1 clinical trial undertaken to assess safety and pharmacokinetics of IHL-675A as an anti-inflammatory drug candidate.

Incannex Contact Information:

Incannex Healthcare Limited

Mr Joel Latham

Managing Director and Chief Executive Officer





Investor Relations Contact – United States

Alyssa Factor

Edison Group

+1 (860) 573 9637





EN
03/05/2023

Underlying

IXHLINCANNEX HEALTHCARE LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INCANNEX HEALTHCARE LTD

 PRESS RELEASE
Free
IXHL INCANNEX HEALTH...

Incannex Healthcare Inc. Announces Pricing of $10 Million Registered D...

Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules NEW YORK and MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IHXL), ("Incannex" or the “Company") a clinical-stage biopharmaceutical company leading the way in developing combination medicines, today announced that it has entered into a securities purchase agreement with healthcare-dedicated institutional investors for the issuance and sale of 2,000,000 shares of its common stock (or common stock equivalents in lieu thereof...

10h / 38m 1 EN
 PRESS RELEASE
Free
IXHL INCANNEX HEALTH...

Incannex Strengthens Clinical Development Pathway for IHL-42X Followin...

Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 program MELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced an enhanced clinical development strategy for IHL-42X, its lead oral drug candidate for the treatment of obstructive sleep apnea (OSA), following statistically si...

10h / 43m 1 EN
 PRESS RELEASE
Free
IXHL INCANNEX HEALTH...

Incannex Announces Reverse Stock Split

Incannex Announces Reverse Stock Split Incannex’s common stock is expected to begin trading on a post-split adjusted basis on February 27, 2026 MELBOURNE, Australia and NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that the board of directors of the Company approved a 1-for-30 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the...

February 25, 2026 1 EN
 PRESS RELEASE
Free
IXHL INCANNEX HEALTH...

Incannex Healthcare Announces Additional Appointments to Clinical Advi...

Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board Expands clinical expertise to support disciplined advancement of the PSX-001 program MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board (“CAB”): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent...

January 29, 2026 1 EN
 PRESS RELEASE
Free
IXHL INCANNEX HEALTH...

Incannex Healthcare Announces Formation of Clinical Advisory Board for...

Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program Strengthens clinical and regulatory guidance as PSX-001 advances to its next phase of development MELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces the formation of a Clinical Advisory Board (CAB) to support the continued advancement of its PSX-001 development program in generalized anxiety disorder. The newly established CAB has been formed to ...

January 22, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch